Pathway information


Pathway Lead
Professor Martin Wilkins

Translational Medicine pathway handbook [download pdf]
Translational Medicine - the student experience

The pathway combines an introduction to the theory behind and technologies currently used in drug discovery, pharmacokinetics, role of biomarkers and surrogate endpoints, preclinical safety assessment, first-time-in-human studies, clinical investigation paradigms, research governance and medical statistics.

Suitable for all medical disciplines, but of particular interest to Cardiovascular/Respiratory, Neuroscience, Oncology, and Metabolic medicine, the programme is highly suitable for graduates in medicine and/or life sciences who wish to pursue a career as clinical academics and for medical professionals in industry.

Teachers from academia and industry and an excellent basic and clinical research infrastructure provide an appropriate environment for advanced, hands-on training in the theoretical and practical aspects of clinical research. This pathway intends to develop highly skilled and motivated academic clinical scientists for the future. 

The pathway has been designed to focus on research and uses some clinical specialities as models to highlight this. While all students will be required to follow this curriculum, the opportunity to specialise in a clinical field will be provided through the research project. The training provided will enable students to put theory into practice by contributing to clinical research activities, taking responsibility for a project and producing a project report. Students will obtain an understanding of research methodologies by studying in a world-leading clinical research environment.


Employment prospects

Graduates will have an awareness of clinical experimental medicine and translational research, which provides an ideal background to students who wish to pursue a PhD and a career in a clinical research environment. The programme intends to develop highly skilled and motivated researchers and cultivate the next generation of physician-scientists involved in the design and execution of conventional and experimental medicine trials. Successful completion of the course is likely to enhance opportunities for recruitment by academic/industry institutions beyond traditional organisational boundaries.


Entry requirements 

The programme is designed to cater forUK and international students with a first/undergraduate degree in Medicine or Life Sciences. Basic scientists with a degree in life sciences are also encouraged to apply. An upper second class Honours is preferred.


Examples of past student projects 

2015

  • Does moderate exercise cause 'athlete's heart' in genotype-negative healthy subjects: A Cardiac MRI analysis.
  • Characterising novel mutations arising from exome sequencing in familial Amyotrophic Lateral Sclerosis.
  • Mitochondrial Dysfunction in Pulmonary Arterial Hypertension.
  • Study of HNF1A antisense lncRNA via single-molecule RNA-FISH and CRISPR/Cas9 knockout EndoC-βH3 beta cell model.
  • Glomerular transcriptomic analysis in glomerulonephritis.
  • Clinical validation of point of Care assays for secretory Phospholipase a2.
  • The use of Field Asymmetric waveform Ion Mobility Spectrometry (FAIMS) in the rapid detection of urinary tract infections.

2014

  • Role of NKB in flushing.
  • The compartmentation of cgmp signalling in human ipsc derived cardiomyocytes.
  • The effects of local anaesthetics on cancer cells.
  • Apelin as a therapeutic prognostic target in hepatocellular carcinoma.
  • Clinical Trial with AT2 receptor antagonist EMA401 for chronic pain in chemotherapy-induced neuropathy (biomarker study).

2013

  • Evaluation of the CXCR4-CXCL12 signalling axis in the mediation of breast cancer resistance to endocrine therapy.
  • Epigenetic Imprints of Mononuclear Cells in Pulmonary Arterial Hypertension.
  • Relapsing-Remitting Multiple Sclerosis Patients Contain a Smaller Proportion of CD19+ CD24hi CD38hi Regulatory B cells which Exhibit a Decreased Capacity to produce IL-10 in Response to CD40 Engagement.
  • Synthesis of recombinant Streptococcus pyogenes surface proteins and their applicability as vaccine candidates.
  • Potential Therapeutic Applications of the Hormone Kisspeptin.
  • Comparing the effects of kisspeptin-10, kisspeptin-54 and GnRH on the reproductive axis in healthy male volunteers.

2012

  • The 18kDa Translocator Protein rs6971 polymorphism - effect on ligand binding and steroid synthesis.
  • Proteomic explorations in Cholangiocarcinoma.
  • Synthesis of recombinant proteins to facilitate development of a novel Staphylococcus aureus diagnostic test.
  • CD98hc: a mediator of mechanotransduction in ventilator-associated lung injury (VALI)?
  • The Apelin-APJ system in idiopathic pulmonary arterial hypertension and healthy volunteers; tissue location and cardiopulmonary     response.

2011

  • The Identification of novel relationships between known candidate cancer-related genes (FOLR1-3, EVI1-MDS1, SCNN1A, OPCML, INPP4B   & PTEN) and the elucidation of their roles in the pathogenesis of epithelial ovarian cancer.
  • The efficacy of Qutenza® (Capsaicin 8% Patches) for the reduction of site pain caused by continuous subcutaneous infusion of   Remodulin® (Treprostinil Sodium) in Pulmonary Arterial Hypertension patients. 2) The effect of Translocator Protein Binding Status on  steroid production.
  • Evaluation of sodium MRI in osteoarthritis using WORMS score on conventional MRI and KL score on plain radiography 2) Myoinositol as a biomarker of malignant transformation due to microglial activation: Evaluation using multimodal MRI and histopathology.
  • The role of cell-free DNA in Idiopathic Pulmonary Arterial Hypertension.
  • The effect of kisspeptin and neurokinin B on reproductive hormone release in humans. 1. The effect of kisspeptin-10 on reproductive hormone release in humans. 2. The effect of neurokinin B administration on healthy male volunteers.
  • Evaluating Biomarkers in Idiopathic Pulmonary Arterial Hypertension. Part One: MicroRNAs Part Two: Choline Kinase and Caspase-3.